Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGENNYSE:AMAMNASDAQ:NVAXNASDAQ:TALS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGENAgenus$4.80+0.4%$3.68$1.38▼$18.74$131.05M1.43663,648 shs750,338 shsAMAMAmbrx Biopharma$28.00$27.94$6.55▼$28.15$1.77B-1.922.12 million shsN/ANVAXNovavax$6.31-1.6%$6.74$5.01▼$17.81$1.04B2.816.35 million shs3.73 million shsTALSTalaris Therapeutics$17.02+2.3%$18.84$0.89▼$27.95$727.84M2.18386,531 shs193,489 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGENAgenus+0.42%-6.61%+25.65%+187.43%-67.03%AMAMAmbrx Biopharma0.00%0.00%0.00%0.00%0.00%NVAXNovavax-1.56%-10.24%-12.97%-16.53%-54.93%TALSTalaris Therapeutics0.00%-15.45%+8.62%-5.51%+8.76%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGENAgenus3.9899 of 5 stars3.23.00.04.61.81.70.6AMAMAmbrx BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ANVAXNovavax4.406 of 5 stars3.12.00.04.71.30.83.1TALSTalaris TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGENAgenus 2.33Hold$14.00191.67% UpsideAMAMAmbrx Biopharma 0.00N/AN/AN/ANVAXNovavax 2.29Hold$17.00169.41% UpsideTALSTalaris Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NVAX, AGEN, TALS, and AMAM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025NVAXNovavaxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSell$6.006/4/2025AGENAgenusRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$4.00 ➝ $6.006/4/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$25.005/19/2025NVAXNovavaxB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/13/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral5/13/2025AGENAgenusRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$3.00 ➝ $4.005/9/2025NVAXNovavaxJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$9.00 ➝ $7.004/30/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral4/21/2025AGENAgenusB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGENAgenus$103.46M1.27N/AN/A($13.06) per share-0.37AMAMAmbrx Biopharma$7.40M238.95N/AN/A$3.05 per share9.18NVAXNovavax$682.16M1.50N/AN/A($3.89) per share-1.62TALSTalaris TherapeuticsN/AN/AN/AN/A$4.33 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGENAgenus-$227.21M-$8.67N/AN/AN/A-196.12%N/A-82.33%8/6/2025 (Estimated)AMAMAmbrx Biopharma-$78MN/A0.00N/AN/AN/AN/AN/AN/ANVAXNovavax-$187.50M$2.652.3878.880.0738.14%-115.51%29.99%8/14/2025 (Estimated)TALSTalaris Therapeutics-$73.89M-$1.79N/A∞N/AN/A-39.93%-37.37%N/ALatest NVAX, AGEN, TALS, and AMAM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025AGENAgenus-$1.61-$1.03+$0.58-$1.03$26.38 million$24.07 million5/8/2025Q1 2025NVAXNovavax$0.71$2.93+$2.22$2.93$204.08 million$666.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGENAgenusN/AN/AN/AN/AN/AAMAMAmbrx BiopharmaN/AN/AN/AN/AN/ANVAXNovavaxN/AN/AN/AN/AN/ATALSTalaris TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGENAgenusN/A0.110.11AMAMAmbrx BiopharmaN/A13.2813.28NVAXNovavaxN/A2.062.03TALSTalaris TherapeuticsN/A15.4115.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGENAgenus61.46%AMAMAmbrx Biopharma77.28%NVAXNovavax53.04%TALSTalaris Therapeutics67.61%Insider OwnershipCompanyInsider OwnershipAGENAgenus5.50%AMAMAmbrx Biopharma0.64%NVAXNovavax1.00%TALSTalaris Therapeutics16.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGENAgenus44027.42 million25.91 millionOptionableAMAMAmbrx Biopharma8763.15 million62.75 millionOptionableNVAXNovavax1,990161.97 million160.35 millionOptionableTALSTalaris Therapeutics8442.76 million35.71 millionNot OptionableNVAX, AGEN, TALS, and AMAM HeadlinesRecent News About These CompaniesTourmaline Bio, Inc. (TRML)August 21, 2024 | finance.yahoo.comCoin Tales Free Spins – Updated Every Day!July 30, 2024 | talkandroid.comCullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial OfficerApril 29, 2024 | finanznachrichten.deLongitude Venture Partners III, L.P.'s Net WorthFebruary 25, 2024 | benzinga.comTalaris Therapeutics (TALS) Price Target Increased by 562.50% to 135.15November 1, 2023 | msn.comTalaris Thera (NASDAQ: TALS) stock to jump 1,000% then fall $15 - weird and complexOctober 20, 2023 | dhakatribune.comTalaris Therapeutics goes ex-dividend tomorrowOctober 19, 2023 | msn.comTalaris Therapeutics, Inc.: Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline BioOctober 18, 2023 | finanznachrichten.deTalaris shareholders approve merger, 1-for-10 reverse stock splitOctober 17, 2023 | msn.comTalaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline BioOctober 17, 2023 | finance.yahoo.comTalaris Therapeutics Inc [TALS] Insider Ildstad Suzanne sells 12,942 Shares – Insider Selling AlertOctober 16, 2023 | knoxdaily.comShares of Talaris Therapeutics Climb 5.2% on Special Dividend Tied to MergerOctober 6, 2023 | marketwatch.comTalaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline BioOctober 6, 2023 | finance.yahoo.comNew York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris TherapeuticsOctober 4, 2023 | finance.yahoo.comWe're Keeping An Eye On Talaris Therapeutics' (NASDAQ:TALS) Cash Burn RateSeptember 12, 2023 | finance.yahoo.comSHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – TALS,August 23, 2023 | bakersfield.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AEL, DEN, TALS, QUOTAugust 15, 2023 | markets.businessinsider.comImmunoFree Inc. has Acquired Talaris Therapeutics, Inc.'s Tolerance BusinessAugust 14, 2023 | finance.yahoo.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NEX, TALS, QUOT, SURFAugust 8, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TALS, NETI, AMED, GHLJuly 29, 2023 | bakersfield.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesSuper Micro Computer Stock's Rally Backed by Strong FinancialsBy Gabriel Osorio-Mazilli | June 19, 2025View Super Micro Computer Stock's Rally Backed by Strong FinancialsWhy Analysts Are Bullish on Celsius Stock After 30% DropBy Gabriel Osorio-Mazilli | June 16, 2025View Why Analysts Are Bullish on Celsius Stock After 30% DropIgnore the Noise—Samsara Stock Is Still a Strong BuyBy Sam Quirke | June 12, 2025View Ignore the Noise—Samsara Stock Is Still a Strong BuyAs Gold Surges, Albemarle Stock May Be the Next to PopBy Gabriel Osorio-Mazilli | June 10, 2025View As Gold Surges, Albemarle Stock May Be the Next to Pop5 Small Cap Stocks With Explosive Upside PotentialBy Ryan Hasson | June 23, 2025View 5 Small Cap Stocks With Explosive Upside PotentialNVAX, AGEN, TALS, and AMAM Company DescriptionsAgenus NASDAQ:AGEN$4.80 +0.02 (+0.42%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$4.95 +0.15 (+3.10%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.Ambrx Biopharma NYSE:AMAMAmbrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California.Novavax NASDAQ:NVAX$6.31 -0.10 (-1.56%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$6.36 +0.06 (+0.87%) As of 06:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.Talaris Therapeutics NASDAQ:TALSTalaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
